Fulgent Genetics, Inc.
For the period ended Dec 31, 2025. Filed Feb 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 27, 2026
FLGT$26.15+10.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
EXHIBIT INDEX
| ExhibitNumber · Description · Form · File Number · Incorporated byReference Exhibit · Filing Date · FiledHerewith | |||||
|---|---|---|---|---|---|
| 2.1 | Agreement and Plan Merger, dated September 16, 2016, by and among the registrant, Fulgent MergerSub, LLC and Fulgent Therapeutics LLC. | S-1/A | 333-213469 | 2.1 | 9/19/2016 |
| 3.1 | Certificate of Incorporation of the registrant, as amended. | 10-Q | 001-37894 | 3.1 | 8/14/2017 |
| 3.1.1 | Certificate of Amendment to Certificate of Incorporation of the registrant, dated August 2, 2016. | 10-Q | 001-37894 | 3.1.1 | 8/14/2017 |
| 3.1.2 | Certificate of Amendment to Certificate of Incorporation of the registrant, dated May 17, 2017. | 10-Q | 001-37894 | 3.1.2 | 8/14/2017 |
| 3.2 | Amended and Restated Bylaws. | 10-Q | 001-37894 | 3.2 | 8/4/2023 |
| 4.1 | Form of Certificate of Common Stock of the registrant. | S-1/A | 333-213469 | 4.1 | 9/19/2016 |
| 4.2 | Description of the registrant’s securities. | 10-K | 001-37894 | 4.2 | 2/28/2025 |
| 10.1# | Form of Indemnification Agreement between the registrant and each of its officers and directors. | S-1 | 333-213469 | 10.1 | 9/2/2016 |
| 10.2# | Amended and Restated 2015 Equity Incentive Plan of Fulgent Therapeutics LLC. | S-1 | 333-213469 | 10.2 | 9/2/2016 |
| 10.3# | Form of Notice of Option Grant and Option Agreement under the Amended and Restated 2015 Equity Incentive Plan of Fulgent Therapeutics LLC. | S-1 | 333-213469 | 10.3 | 9/2/2016 |
| 10.4# | Form of Notice of Profits Interest Grant and Profits Interest Agreement under the Amended and Restated 2015 Equity Incentive Plan of Fulgent Therapeutics LLC. | S-1 | 333-213469 | 10.4 | 9/2/2016 |
| 10.5# | Form of Notice of Restricted Share Unit Grant and Restricted Share Unit Agreement under the Amended and Restated 2015 Equity Incentive Plan of Fulgent Therapeutics LLC. | S-1 | 333-213469 | 10.5 | 9/2/2016 |
| 10.6# | Form of Notice of Stock Option Award and Stock Option Award Agreement under the 2016 Omnibus Incentive Plan of the registrant. | S-1 | 333-213469 | 10.7 | 9/2/2016 |
| 10.7# | Form of Notice of Restricted Stock Unit Award and Restricted Stock Unit Agreement under the 2016 Omnibus Incentive Plan of the registrant. | 10-K | 001-37894 | 10.8 | 3/17/2017 |
| 10.8# | Form of Option Substitution Award under the 2016 Omnibus Incentive Plan of the registrant. | S-1 | 333-213469 | 10.9 | 9/2/2016 |
| 10.9# | Form of Notice of Restricted Stock Unit Substitution Award and Restricted Stock Unit Agreement under the 2016 Omnibus Incentive Plan of the registrant. | S-1 | 333-213469 | 10.10 | 9/2/2016 |
| 10.10# | Employment Agreement, dated May 25, 2016, by and among Fulgent Therapeutics LLC, the registrant and Ming Hsieh. | S-1 | 333-213469 | 10.11 | 9/2/2016 |
| 10.11# | Employment Agreement, dated May 25, 2016, by and among Fulgent Therapeutics LLC, the registrant and Paul Kim. | S-1 | 333-213469 | 10.12 | 9/2/2016 |
| 10.12# | Amended and Restated Employment Agreement, dated May 25, 2016, by and among Fulgent Therapeutics LLC, the registrant and Hanlin Gao. | S-1 | 333-213469 | 10.13 | 9/2/2016 |
| 10.13# | Severance Agreement, dated July 7, 2016, by and among Fulgent Therapeutics LLC, the registrant and Ming Hsieh. | S-1 | 333-213469 | 10.14 | 9/2/2016 |
| 10.14# | Severance Agreement, dated July 7, 2016, by and among Fulgent Therapeutics LLC, the registrant and Paul Kim. | S-1 | 333-213469 | 10.15 | 9/2/2016 |
| 10.15# | Severance Agreement, dated July 7, 2016, by and among Fulgent Therapeutics LLC, the registrant and Hanlin Gao. | S-1 | 333-213469 | 10.16 | 9/2/2016 |
| 10.16 | Contribution and Allocation Agreement, dated May 19, 2016, by and among Fulgent Therapeutics LLC, Fulgent Pharma LLC and Ming Hsieh. | S-1 | 333-213469 | 10.17 | 9/2/2016 |
| 10.17 | Form of Fourth Amended and Restated Operating Agreement of Fulgent Therapeutics LLC, to be in effect upon completion of the Reorganization. | S-1/A | 333-213469 | 2.1 | 9/19/2016 |
| 10.18§ | Cooperation Agreement on the Establishment of Fujian Fujun Gene Biotech Co., Ltd., dated April 25, 2017, by and among Shenzhen Fujin Gene Science & | 10-Q | 001-37894 | 10.1 | 8/14/2017 |
| ExhibitNumber | Description | Form | File Number | Incorporated byReference Exhibit | Filing Date | FiledHerewith |
|---|---|---|---|---|---|---|
| Technology Co., Ltd., Xilong Scientific Co., Ltd. and Fuzhou Jinqiang Investment Partnership (LP). | ||||||
| 10.19# | Employment Agreement, dated March 8, 2021, by and among Fulgent Therapeutics, LLC, the registrant and Jian Xie. | 10-K | 001-37894 | 10.37 | 3/8/2021 | |
| 10.20# | Severance Agreement, dated March 8, 2021, by and among Fulgent Therapeutics LLC, the registrant and Jian Xie. | 10-K | 001-37894 | 10.38 | 3/8/2021 | |
| 10.21** | Restructuring Agreement of Fujian Fujun Gene Biotech Co., Ltd. | 10-Q | 001-37894 | 10.1 | 8/10/2021 | |
| 10.22# | Fulgent Genetics, Inc. Incentive Compensation Recoupment Policy. | 8-K | 001-37894 | 10.1 | 3/29/2022 | |
| 10.23 | Agreement and Plan of Merger, dated as of April 16, 2022, by and among Fulgent Therapeutics LLC, solely for purpose of Section 6.20, the registrant, Ducks Acquisition Sub, Inc., Symphony Buyer, Inc., solely in its capacity as the representative of Symphony’s securityholders, Avista Capital Partners IV GP, L.P. and solely for purposes of Section 6.21, Article VIII and Section 10.14, those company stockholders set forth on the signature page thereto. | 8-K | 001-37894 | 2.1 | 4/26/2022 | |
| 10.24# | Form of Notice of Restricted Stock Unit Award and Restricted Stock Unit Agreement under the Fulgent Pharma Holdings, Inc. 2022 Omnibus Incentive Plan. | 10-Q | 001-37894 | 10.2 | 11/7/2022 | |
| 10.25^ | Agreement and Plan of Merger, dated November 7, 2022 by and among the registrant, FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc. and solely for purposes of Section 2.4, Section 5.5, Article VI, Section 7.8 and Section 7.14, those company stockholders set forth on the signature page thereto. | 10-Q | 001-37894 | 10.3 | 11/7/2022 | |
| 10.26^# | Amended and Restated Executive Officer Incentive Plan of the registrant. | 10-Q | 001-37894 | 10.2 | 11/3/2023 | |
| 10.27 | Lease Agreement of Premises at 15-19 Crawford Street Needham, Massachusetts, by and between Inform Diagnostics and Crawford Street DE, LLC. | 10-K | 001-37894 | 10.51 | 2/28/2023 | |
| 10.28# | Fulgent Pharma Holdings, Inc. 2022 Omnibus Incentive Plan. | 10-K | 001-37894 | 10.52 | 2/28/2023 | |
| 10.29*^# | Amended and Restated Director Compensation Program of the registrant. | 10-Q | 001-37894 | 10.1 | 5/5/2023 | |
| 10.30 | Executive Officer Incentive Plan of the registrant. | 10-Q | 001-37894 | 10.3 | 5/5/2023 | |
| 10.31 | Amended and Restated 2016 Omnibus Incentive Plan of the registrant. | 8-K | 001-37894 | 10.1 | 5/18/2023 | |
| 10.32^ | Purchase and Sale Agreement, dated December 20, 2025, by and among Bako Pathology LP, Bako Pathology Holdings Corp., BPA Holding Corp., Dermatopathology Experts, LLC, and Inform Diagnostics, Inc. | 8-K | 001-37894 | 10.1 | 12/22/2025 | |
| 10.33^ | Asset Purchase Agreement, dated December 20, 2025, by and among Bako Pathology LP, Bako Pathology Holdings Corp., BPA Holding Corp., Bakotic Pathology Associates, L.L.C., Podceuticals L.L.C., GBRL Consulting, LLC, Fulgent Therapeutics, LLC, and Inform Diagnostics, Inc. | 8-K | 001-37894 | 10.2 | 12/22/2025 | |
| 19.1 | Insider Trading Policy. | 10-K | 001-37894 | 19.1 | 2/28/2025 | |
| 21.1 | Subsidiaries of the registrant. | X | ||||
| 23.1 | Consent of Deloitte & Touche LLP, independent registered public accounting firm, relating to the financial statements of the registrant. | X | ||||
| 24.1 | Power of Attorney (included on the signature page hereto). | X | ||||
| 31.1 | Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | ||||
| 31.2 | Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | ||||
| ExhibitNumber | Description | Form | File Number | Incorporated byReference Exhibit | Filing Date | FiledHerewith |
|---|---|---|---|---|---|---|
| 32.1* · Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. · X | ||||||
| 97.1^# | Amended and Restated Incentive Compensation Recoupment Policy of the registrant. | 10-Q | 001-37894 | 10.1 | 11/3/2023 | |
| 101.INS | Inline XBRL Instance Document – the instance document does not appear inthe Interactive Data File because XBRL tags are embedded within the InlineXBRL document. | X | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document. | X | ||||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | X | ||||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document. | X | ||||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document. | X | ||||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | X | ||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | X | ||||
- This certification is being furnished solely to accompany this report pursuant to 18 U.S.C. 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation by reference language in such filing.
** Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted by means of marking such portions with asterisks as the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.